Researchers at the University of Cambridge have developed software that takes super-resolution microscope scans and transforms them into a virtual, 3D worlds, allowing scientists to don a virtual reality headset and take an interactive tour of individual cells and proteins.

LivaNova delivered new data from its sutureless aortic heart valve, showing fewer complications and stronger clinical outcomes compared to traditional implants built on a stent frame.

The sting from a Korean yellow-jacket wasp doesn’t pose much of a danger to people—but it could be toxic enough to kill lethal bacteria that have become resistant to antibiotics. Now the insect has inspired scientists at the University of Pennsylvania’s Perelman School of Medicine to take a new approach to developing antibiotics.

Dialysis giant Fresenius Medical Care has laid out a new five-year strategy to further expand the reach of its business beyond kidney disease by offering a portfolio of intensive care support products for failing hearts, lungs and other organs.

Avail Medsystems has raised $100 million to support its system for virtually connecting surgeons with remote experts and medtech company representatives during a live procedure.

Olympus has begun rolling out an artificial-intelligence-powered platform for its new endoscope, designed to automatically spot suspicious lesions and polyps during a colonoscopy in real time.

Messenger RNA (mRNA) candidates are among the front-runners in the race for a COVID-19 vaccine, with Moderna and the Pfizer-BioNTech tandem each planning to seek an emergency approval later this year. But vaccination is just the tip of the iceberg for mRNA technologies, which Yusuf Erkul, M.D., thinks could be more useful as treatments for cancer, COVID-19 and beyond.

Genentech has inked a multiyear partnership with Imbio to develop artificial-intelligence-powered imaging diagnostics for lung diseases for use within the Roche division’s clinical trials, as well as more broadly by physicians.

Amgen and Cytokinetics’ heart drug omecamtiv mecarbil hit the mark in a phase 3 study, beating placebo at warding off hospitalizations and other interventions in patients with a type of chronic heart failure. But even though the study technically succeeded, the drug did not help patients live longer—and industry watchers weren’t impressed.

As Arrowhead continues its turnaround, this election cycle is looking like a new era compared to the last as it strikes a major billion-dollar deal with Takeda.